A Down syndrome trial of tofacitinib, a drug already approved for rheumatoid arthritis, met its safety goal and reduced the overactive immune signaling linked to the condition, the University of Colorado Anschutz Medical Campus said Nov. 18. This result, more than six years after the trial began, gives researchers a drug that is already on pharmacy shelves and a clear next test for whether it helps more than the skin and the bloodwork.
What the Down Syndrome Trial Found
The phase 2 study, published in Cell Reports Medicine, gave adolescents and adults with Down syndrome tofacitinib twice a day for 16 weeks, with an optional extension to 40 weeks, according to the release. It met its predefined safety endpoint.
Interferon activity, a measure of the immune overdrive the trial targeted, dropped significantly. So did inflammatory cytokine scores and quinolinic acid. Two skin conditions improved: hidradenitis suppurativa, which causes painful lumps, and alopecia areata, which causes hair loss.
“We have demonstrated that we can reduce excessive immune activity and improve certain inflammatory conditions,” said Joaquín Espinosa, executive director of the Linda Crnic Institute for Down Syndrome, in the release.
Six Years from Launch to Results
When the trial opened in March 2020, the university described tofacitinib as already approved by the FDA for rheumatoid and psoriatic arthritis, and cited CDC figures that about 6,000 babies with Down syndrome are born in the U.S. each year. A calculation from the two dates: results arrived about six years and eight months after launch. Repurposing an approved drug is the shortcut in this story. Its safety profile in adults is already known, which lowers the cost and risk of each next step.
Limits of the Tofacitinib Results
The trial was open-label and single-arm, which means every participant knew they were getting the drug and there was no placebo group. JAK inhibitors also carry known risks. The team was careful on cognition. “The neuropsychological results are intriguing, but they are not yet proof that this medicine improves cognition,” said Lina Patel, a professor of psychiatry and a co-author.
That proof is the job of the next trial. MISSION-1, a double-blind, placebo-controlled study of tofacitinib in people with Down syndrome ages 6 to 22, gives six months of treatment with visits in Denver, according to the Crnic Institute. A separate trial in Down Syndrome Regression Disorder reports results in 2027. The work was funded by the NIH INCLUDE Project, the Global Down Syndrome Foundation, the Anna and John J. Sie Foundation and the Ruth E. Olleman Trust.



